{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:33:23Z","timestamp":1759937603739,"version":"3.40.5"},"reference-count":16,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T00:00:00Z","timestamp":1578268800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Intern J of Cosmetic Sci"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>A randomized study was designed to evaluate the potential cosmetic benefit of a biomimetic, niacinamide\u2010containing moisturizing cream in oily, blemish\u2010prone skin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Healthy adult women with oily, blemish\u2010prone skin were randomized to one of three treatment groups: test, control, or positive control. In the test group, subjects used the test product (containing 4% niacinamide), plus the standard cleanser (Simple\u00ae Kind to Skin Moisturizing Facial Wash). In the control group, subjects received no moisturizer but used the standard cleanser. In the positive control group, subjects used Vivatinell Acnecinamide<jats:sup>\u00ae<\/jats:sup> Gel Cream (containing 4% niacinamide) as a moisturizer and Neutrogena Visibly Clear<jats:sup>\u00ae<\/jats:sup> Spot Clearing Facial Wash (containing 2% salicylic acid) as a cleanser. The positive control regimen was included to provide a comparison for estimates of effect size. The primary objective was to evaluate skin moisturization as a change from baseline in corneometer values at 8\u00a0h for the test regimen vs. the control regimen. Analysis of covariance was applied for the primary efficacy analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 132 subjects were randomized with 44 included in each treatment group. A significant difference was observed in the primary endpoint for the test regimen compared with the control regimen (least\u2010squares mean difference [95% CI]: 3.12 [0.68, 5.56], <jats:italic>P<\/jats:italic>\u00a0=\u00a00.0128). A trend was observed in favour of the positive control regimen compared with the control regimen. Secondary measurements of moisturization supported the primary efficacy outcome. Assessment of blemishes showed a significant difference between the test regimen vs. the control regimen for change from baseline in mean total blemish count at Week 8 (least\u2010squares mean difference [95% CI]: \u22121.80 [\u22123.41, \u22120.19], <jats:italic>P<\/jats:italic>\u00a0=\u00a00.0290). No statistical comparisons between the positive control group and the test group were performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study provides proof\u2010of\u2010concept evidence that a novel lamellar lipid moisturizer containing niacinamide, in combination with a standard cleanser, can help moisturize the skin and provide an overall improvement in the complexion appearance of people with blemish\u2010prone skin. Study registration: NCT03093181.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ics.12576","type":"journal-article","created":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T22:26:00Z","timestamp":1567031160000},"page":"29-35","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cosmetic benefits of a novel biomimetic lamellar formulation containing niacinamide in healthy females with oily, blemish\u2010prone skin in a randomized proof\u2010of\u2010concept study"],"prefix":"10.1111","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0247-9241","authenticated-orcid":false,"given":"J.-P.","family":"Santos-Caetano","sequence":"first","affiliation":[{"name":"GlaxoSmithKline Brazil S\u00e3o Paulo \u2010 Medical Affairs and Clinical Operations S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. F.","family":"Gfeller","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Consumer Healthcare Medical Affairs \u2013 Skin Health St George's Avenue Weybridge UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Mahalingam","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Consumer Healthcare Medical Affairs \u2013 Skin Health 184 Liberty Corner Road Warren NJ 07059 USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Thompson","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Consumer Healthcare Research and Development \u2013 Skin Health St George's Avenue Weybridge KT13 0DE UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. J.","family":"Moore","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Consumer Healthcare Research and Development \u2013 Skin Health St George's Avenue Weybridge KT13 0DE UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Vila","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Brazil S\u00e3o Paulo \u2010 Medical Affairs and Clinical Operations S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Doi","sequence":"additional","affiliation":[{"name":"Azidus Brasil \u2010 507 Rua General Os\u00f3rio Valinhos Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. R.","family":"Cargill","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Consumer Healthcare Medical Affairs \u2013 Skin Health St George's Avenue Weybridge UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,1,6]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.5114\/ada.2018.73159"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/ics.12366"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jpcb.8b00747"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/ics.12499"},{"volume-title":"Propionibacterium acnes and chronic diseases \u2013 The infectious etiology of chronic diseases","year":"2004","author":"Bhatia A.","key":"e_1_2_9_6_1"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000359974"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2000.03705.x"},{"issue":"6","key":"e_1_2_9_9_1","first-page":"8","article-title":"Topical niacinamide and barrier enhancement","volume":"70","author":"Bissett D.","year":"2002","journal-title":"Cutis"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/14764170600717704"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12002"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2494.2011.00658.x"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2004.02375.x"},{"key":"e_1_2_9_14_1","unstructured":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).https:\/\/www.ich.org\/home.html(last accessed July 2019)."},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S84765"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.5455\/gulhane.22956"},{"key":"e_1_2_9_17_1","article-title":"Investigation of efficacy of topical niacinamide for the treatment of mild and moderate Acne Vulgaris","volume":"2","author":"Kaymak Y.","year":"2008","journal-title":"J. Turk. Acad. Dermatol."}],"container-title":["International Journal of Cosmetic Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ics.12576","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ics.12576","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ics.12576","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T03:56:20Z","timestamp":1694145380000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ics.12576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,6]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1111\/ics.12576"],"URL":"https:\/\/doi.org\/10.1111\/ics.12576","archive":["Portico"],"relation":{},"ISSN":["0142-5463","1468-2494"],"issn-type":[{"type":"print","value":"0142-5463"},{"type":"electronic","value":"1468-2494"}],"subject":[],"published":{"date-parts":[[2020,1,6]]},"assertion":[{"value":"2019-03-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}